Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Saved in:
| Title: | Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. |
|---|---|
| Authors: | Moore, Kathleen N.1,2 (AUTHOR) Kathleen-Moore@ouhsc.edu, Birrer, Michael J.1,3 (AUTHOR), Marsters, Jim4 (AUTHOR), Wang, Yulei4 (AUTHOR), Choi, YounJeong4 (AUTHOR), Royer-Joo, Stephanie4 (AUTHOR), Lemahieu, Vanessa4 (AUTHOR), Armstrong, Katy4 (AUTHOR), Cordova, Julie4 (AUTHOR), Samineni, Divya4 (AUTHOR), Schuth, Eva4 (AUTHOR), Vaze, Anjali4 (AUTHOR), Maslyar, Daniel1,4 (AUTHOR), Humke, Eric W.1,4 (AUTHOR), Hamilton, Erika P.5 (AUTHOR), Liu, Joyce F.6 (AUTHOR) |
| Source: | Gynecologic Oncology. Sep2020, Vol. 158 Issue 3, p631-639. 9p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00908258 |
|---|---|
| DOI: | 10.1016/j.ygyno.2020.05.039 |
